List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3745649/publications.pdf Version: 2024-02-01

		101543	128289
223	5,048	36	60
papers	citations	h-index	g-index
221	221	221	(000
231	231	231	6999
all docs	docs citations	times ranked	citing authors

Снім Ніір

#	Article	IF	CITATIONS
1	Trends in esophageal adenocarcinoma incidence and mortality. Cancer, 2013, 119, 1149-1158.	4.1	439
2	Prognostic Gene Expression Signature for Patients With Hepatitis C–Related Early-Stage Cirrhosis. Gastroenterology, 2013, 144, 1024-1030.	1.3	195
3	The Cost Effectiveness of Radiofrequency Ablation for Barrett's Esophagus. Gastroenterology, 2012, 143, 567-575.	1.3	143
4	Disparities in cancer outcomes across age, sex, and race/ethnicity among patients with pancreatic cancer. Cancer Medicine, 2018, 7, 525-535.	2.8	136
5	Risks and Benefits of Infliximab for the Treatment of Crohn's Disease. Clinical Gastroenterology and Hepatology, 2006, 4, 1017-1024.	4.4	130
6	Hepatitis C Disease Burden in the United States in the era of oral directâ€acting antivirals. Hepatology, 2016, 64, 1442-1450.	7.3	126
7	Predictors of households at risk for food insecurity in the United States during the COVID-19 pandemic. Public Health Nutrition, 2021, 24, 3929-3936.	2.2	86
8	Optimal timing of hepatitis C treatment for patients on the liver transplant waiting list. Hepatology, 2017, 65, 777-788.	7.3	83
9	Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving. Clinical Gastroenterology and Hepatology, 2017, 15, 827-837.e8.	4.4	81
10	Gastric adenocarcinoma screening and prevention in the era of new biomarker and endoscopic technologies: a cost-effectiveness analysis. Gut, 2016, 65, 563-574.	12.1	80
11	Bariatric surgery for nonalcoholic steatohepatitis: A clinical and costâ€effectiveness analysis. Hepatology, 2017, 65, 1156-1164.	7.3	76
12	Cost-effectiveness of photodynamic therapy for treatment of Barrett's esophagus with high grade dysplasia. Digestive Diseases and Sciences, 2003, 48, 1273-1283.	2.3	74
13	Radiofrequency Ablation versus Nephron-sparing Surgery for Small Unilateral Renal Cell Carcinoma: Cost-effectiveness Analysis. Radiology, 2008, 248, 169-178.	7.3	71
14	Longâ€ŧerm clinical impact and costâ€effectiveness of obeticholic acid for the treatment of primary biliary cholangitis. Hepatology, 2017, 65, 920-928.	7.3	70
15	Cost-Effectiveness of Aspirin Chemoprevention for Barrett's Esophagus. Journal of the National Cancer Institute, 2004, 96, 316-325.	6.3	67
16	Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis. Digestive Diseases and Sciences, 2016, 61, 2108-2117.	2.3	67
17	Costâ€effectiveness of treatment and endoscopic surveillance of precancerous lesions to prevent gastric cancer. Cancer, 2010, 116, 2941-2953.	4.1	65
18	Individuals with Down syndrome hospitalized with COVID-19 have more severe disease. Genetics in Medicine, 2021, 23, 576-580.	2.4	65

#	Article	IF	CITATIONS
19	The Management of Small Polyps Found by Virtual Colonoscopy: Results of a Decision Analysis. Clinical Gastroenterology and Hepatology, 2007, 5, 237-244.	4.4	63
20	Cost-effectiveness of Bariatric Surgery in Adolescents With Obesity. JAMA Surgery, 2017, 152, 136.	4.3	62
21	Exploring the Recent Trend in Esophageal Adenocarcinoma Incidence and Mortality Using Comparative Simulation Modeling. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 997-1006.	2.5	61
22	Should we treat acute hepatitis C? A decision and costâ€effectiveness analysis. Hepatology, 2018, 67, 837-846.	7.3	61
23	Correlation of Polyp Number and Family History of Colon Cancer With Germline Mutations. Clinical Gastroenterology and Hepatology, 2005, 3, 1022-1028.	4.4	59
24	A Combination of Esomeprazole and Aspirin Reduces Tissue Concentrations of Prostaglandin E2 in Patients With Barrett's Esophagus. Gastroenterology, 2012, 143, 917-926.e1.	1.3	58
25	Aspirin Protects Against Barrett's Esophagus in a Multivariate Logistic Regression Analysis. Clinical Gastroenterology and Hepatology, 2012, 10, 722-727.	4.4	57
26	Lung cancer costs by treatment strategy and phase of care among patients enrolled in Medicare. Cancer Medicine, 2019, 8, 94-103.	2.8	54
27	Systematic review: costâ€effectiveness of directâ€acting antivirals for treatment of hepatitis C genotypes 2â€6. Alimentary Pharmacology and Therapeutics, 2017, 46, 711-721.	3.7	52
28	Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device. Clinical Gastroenterology and Hepatology, 2017, 15, 1397-1404.e7.	4.4	51
29	Transplanting hepatitis C virus–positive livers into hepatitis C virus–negative patients with preemptive antiviral treatment: A modeling study. Hepatology, 2018, 67, 2085-2095.	7.3	50
30	An analysis of the potential impact of computed tomographic colonography (virtual colonoscopy) on colonoscopy demand. Gastroenterology, 2004, 127, 1312-1321.	1.3	47
31	The Impact of a Prior Diagnosis of Barrett's Esophagus on Esophageal Adenocarcinoma Survival. American Journal of Gastroenterology, 2017, 112, 1256-1264.	0.4	45
32	Strategies for the Prevention of Postoperative Recurrence in Crohn's Disease: Results of a Decision Analysis. American Journal of Gastroenterology, 2011, 106, 2009-2017.	0.4	44
33	Can Mucosal Healing Be a Cost-effective Endpoint for Biologic Therapy in Crohn's Disease? A Decision Analysis. Inflammatory Bowel Diseases, 2013, 19, 37-44.	1.9	43
34	Metformin Does Not Reduce Markers of Cell Proliferation in Esophageal Tissues of Patients With Barrett's Esophagus. Clinical Gastroenterology and Hepatology, 2015, 13, 665-672.e4.	4.4	42
35	Cost-effectiveness Analysis of Bariatric Surgery for Patients With Nonalcoholic Steatohepatitis Cirrhosis. JAMA Network Open, 2019, 2, e190047.	5.9	42
36	The Impact of Obesity on the Rise in Esophageal Adenocarcinoma Incidence: Estimates from a Disease Simulation Model. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2450-2456.	2.5	38

#	Article	IF	CITATIONS
37	Racial/ethnic disparities in colorectal cancer treatment utilization and phase-specific costs, 2000-2014. PLoS ONE, 2020, 15, e0231599.	2.5	38
38	Consensus Guidelines in the Management of Branch Duct Intraductal Papillary Mucinous Neoplasm: A Cost-Effectiveness Analysis. Digestive Diseases and Sciences, 2010, 55, 852-860.	2.3	37
39	The impact of directâ€acting antiâ€virals on the hepatitis C care cascade: identifying progress and gaps towards hepatitis C elimination in the United States. Alimentary Pharmacology and Therapeutics, 2019, 50, 66-74.	3.7	37
40	Effect and cost-effectiveness of national gastric cancer screening in Japan: a microsimulation modeling study. BMC Medicine, 2020, 18, 257.	5.5	37
41	Coxibs Versus Combination NSAID and PPI Therapy for Chronic Pain: An Exploration of the Risks, Benefits, and Costs. Annals of Pharmacotherapy, 2006, 40, 1052-1063.	1.9	36
42	The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1012-1023.	2.5	35
43	Model to Determine the Optimal Dietary Elimination Strategy forÂTreatment of Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology, 2018, 16, 1730-1737.e2.	4.4	35
44	Targeted Screening of Individuals at High Risk for Pancreatic Cancer: Results of a Simulation Model. Radiology, 2015, 275, 177-187.	7.3	34
45	Early Pancreatic Ductal Adenocarcinoma Survival Is Dependent on Size. Pancreas, 2016, 45, 1062-1066.	1.1	33
46	Gender differences in prescription opioid use and misuse: Implications for men's health and the opioid epidemic. Preventive Medicine, 2020, 131, 105946.	3.4	33
47	Progression to pancreatic ductal adenocarcinoma from pancreatic intraepithelial neoplasia: Results of a simulation model. Pancreatology, 2018, 18, 928-934.	1.1	32
48	Effect of the Coronavirus 2019 Pandemic on Outcomes for Patients Admitted With Gastrointestinal Bleeding in New York City. Gastroenterology, 2020, 159, 1155-1157.e1.	1.3	32
49	Analysis of Barriers to and Patients' Preferences for CT Colonography for Colorectal Cancer Screening in a Nonadherent Urban Population. American Journal of Roentgenology, 2010, 195, 393-397.	2.2	31
50	Low-Cost High-Resolution Microendoscopy for the Detection of Esophageal Squamous Cell Neoplasia: An International Trial. Gastroenterology, 2015, 149, 321-329.	1.3	31
51	Contribution of H. pylori and Smoking Trends to US Incidence of Intestinal-Type Noncardia Gastric Adenocarcinoma: A Microsimulation Model. PLoS Medicine, 2013, 10, e1001451.	8.4	30
52	Impact of quality of care on racial disparities in survival for endometrial cancer. American Journal of Obstetrics and Gynecology, 2020, 223, 396.e1-396.e13.	1.3	30
53	Race, Ethnicity, Sex, and Obesity: Is It Time to Personalize the Scale?. Mayo Clinic Proceedings, 2019, 94, 362-363.	3.0	29
54	PREVALENCE OF ANTIBODY TO HUMAN HERPESVIRUS 6 AMONG BLOOD DONORS INFECTED WITH HIV. Lancet. The, 1988, 332, 1146.	13.7	28

#	Article	IF	CITATIONS
55	Treatment of Barrett's Esophagus With High-Grade Dysplasia or Cancer: Predictors of Surgical Versus Endoscopic Therapy. Clinical Gastroenterology and Hepatology, 2008, 6, 1206-1211.	4.4	28
56	Disease Course and Outcomes of COVID-19 Among Hospitalized Patients With Gastrointestinal Manifestations. Clinical Gastroenterology and Hepatology, 2021, 19, 1402-1409.e1.	4.4	28
57	Statins and Aspirin for Chemoprevention in Barrett's Esophagus: Results of a Cost-Effectiveness Analysis. Cancer Prevention Research, 2014, 7, 341-350.	1.5	27
58	Upper Endoscopy in Patients with Acute Myocardial Infarction and Upper Gastrointestinal Bleeding: Results of a Decision Analysis. Digestive Diseases and Sciences, 2009, 54, 701-711.	2.3	26
59	The costâ€effectiveness of pharmacotherapy and lifestyle intervention in the treatment of obesity. Obesity Science and Practice, 2020, 6, 162-170.	1.9	26
60	Risk of Adverse Outcomes in Hospitalized Patients With Autoimmune Disease and COVID-19: A Matched Cohort Study From New York City. Journal of Rheumatology, 2021, 48, 454-462.	2.0	26
61	Development of an Empirically Calibrated Model of Gastric Cancer in Two High-Risk Countries. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 1179-1187.	2.5	25
62	Rescreening of Persons With a Negative Colonoscopy Result: Results From a Microsimulation Model. Annals of Internal Medicine, 2012, 157, 611.	3.9	25
63	Optimization of Prehospital Triage of Patients With Suspected Ischemic Stroke. Stroke, 2018, 49, 2532-2535.	2.0	25
64	Association of Neighborhood Deprivation Index With Success in Cancer Care Crowdfunding. JAMA Network Open, 2020, 3, e2026946.	5.9	25
65	Cost Effectiveness of Transplanting HCV-Infected Livers Into Uninfected Recipients With Preemptive Antiviral Therapy. Clinical Gastroenterology and Hepatology, 2019, 17, 739-747.e8.	4.4	24
66	Costâ€effectiveness of immune checkpoint inhibitors for microsatellite instability–high/mismatch repair–deficient metastatic colorectal cancer. Cancer, 2019, 125, 278-289.	4.1	24
67	Where Have All the Emergencies Gone? The Impact of the COVID-19 Pandemic on Obstetric and Gynecologic Procedures and Consults at a New York City Hospital. Journal of Minimally Invasive Gynecology, 2020, 28, 1411-1419.e1.	0.6	24
68	Persistent effects of the COVID-19 pandemic on diet, exercise, risk for food insecurity, and quality of life: A longitudinal study among U.S. adults. Appetite, 2021, 167, 105639.	3.7	24
69	Thirty‥ear Risk of Cardiovascular Disease Events in Adolescents with Severe Obesity. Obesity, 2020, 28, 616-623.	3.0	24
70	Using machine learning to create prognostic systems for endometrial cancer. Gynecologic Oncology, 2020, 159, 744-750.	1.4	23
71	Cost Effectiveness of Pre– vs Post–Liver Transplant Hepatitis C Treatment With Direct-Acting Antivirals. Clinical Gastroenterology and Hepatology, 2018, 16, 115-122.e10.	4.4	21
72	Use of fertility preservation services in female reproductive-aged cancer patients. American Journal of Obstetrics and Gynecology, 2019, 221, 328.e1-328.e16.	1.3	21

#	Article	IF	CITATIONS
73	Esophageal cancer treatment costs by phase of care and treatment modality, 2000â€⊉013. Cancer Medicine, 2019, 8, 5158-5172.	2.8	21
74	Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis. Clinical Gastroenterology and Hepatology, 2017, 15, 1471-1474.	4.4	20
75	Patterns and predictors of endâ€ofâ€life care in older patients with pancreatic cancer. Cancer Medicine, 2018, 7, 6401-6410.	2.8	20
76	Incidence and Predictors of Adenocarcinoma Following Endoscopic Ablation of Barrett's Esophagus. Digestive Diseases and Sciences, 2014, 59, 1560-1566.	2.3	19
77	Combating Gastric Cancer in Alaska Native People: An Expert and Community Symposium. Gastroenterology, 2020, 158, 1197-1201.	1.3	19
78	Variation in long-term oncologic outcomes by type of cancer center accreditation: An analysis of a SEER-Medicare population with pancreatic cancer. American Journal of Surgery, 2020, 220, 29-34.	1.8	19
79	The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals. Cancer, 2004, 101, 189-197.	4.1	18
80	Quality of life in patients with various Barrett's esophagus associated health states. Health and Quality of Life Outcomes, 2006, 4, 45.	2.4	18
81	Certolizumab Pegol Compared to Natalizumab in Patients with Moderate to Severe Crohn's Disease: Results of a Decision Analysis. Digestive Diseases and Sciences, 2012, 57, 472-480.	2.3	18
82	Survival Disparities by Race and Ethnicity in Early Esophageal Cancer. Digestive Diseases and Sciences, 2018, 63, 2880-2888.	2.3	18
83	Patient Preferences for the Chemoprevention of Esophageal Adenocarcinoma in Barrett's Esophagus. American Journal of Gastroenterology, 2008, 103, 2432-2442.	0.4	17
84	Staging MR Lymphangiography of the Axilla for Early Breast Cancer: Cost-Effectiveness Analysis. American Journal of Roentgenology, 2008, 191, 1308-1319.	2.2	17
85	Cost-effectiveness of endoscopic surveillance of gastric ulcers to improve survival. Gastrointestinal Endoscopy, 2010, 72, 33-43.	1.0	17
86	How to Value Technological Innovation: A Proposal for Determining Relative Clinical Value. Gastroenterology, 2013, 144, 5-8.	1.3	17
87	Surgical vs Endoscopic Management of T1 Esophageal Adenocarcinoma: A Modeling Decision Analysis. Clinical Gastroenterology and Hepatology, 2018, 16, 392-400.e7.	4.4	17
88	Gene-Specific Variation in Colorectal Cancer Surveillance Strategies for Lynch Syndrome. Gastroenterology, 2021, 161, 453-462.e15.	1.3	17
89	Prevalence, Incidence, and Risk of Progression of Asymptomatic Pancreatic Cysts in Large Sample Real-world Data. Pancreas, 2021, 50, 1287-1292.	1.1	17
90	Estimated Cost-effectiveness of Medical Therapy, Sleeve Gastrectomy, and Gastric Bypass in Patients With Severe Obesity and Type 2 Diabetes. JAMA Network Open, 2022, 5, e2148317.	5.9	17

#	Article	IF	CITATIONS
91	Screening and surveillance for Barrett's esophagus. Current Opinion in Gastroenterology, 2012, 28, 377-381.	2.3	16
92	Hospice use and endâ€ofâ€life care among older patients with esophageal cancer. Health Science Reports, 2018, 1, e76.	1.5	16
93	Low Prevalence of Suspected Barrett's Esophagus in Patients With Gastroesophageal Reflux Disease Without Alarm Symptoms. Clinical Gastroenterology and Hepatology, 2019, 17, 857-863.	4.4	16
94	Optimal Timing of Total Gastrectomy to Prevent Diffuse Gastric Cancer in Individuals With Pathogenic Variants in CDH1. Clinical Gastroenterology and Hepatology, 2020, 18, 822-829.e4.	4.4	16
95	Patient Preferences for the Management of High-Grade Dysplasia in Barrett?s Esophagus. Digestive Diseases and Sciences, 2005, 50, 116-125.	2.3	15
96	Development, Calibration, and Validation of a U.S. White Male Population-Based Simulation Model of Esophageal Adenocarcinoma. PLoS ONE, 2010, 5, e9483.	2.5	15
97	Optimizing Management of Patients With Barrett's Esophagus and Low-Grade or No Dysplasia Based on Comparative Modeling. Clinical Gastroenterology and Hepatology, 2020, 18, 1961-1969.	4.4	15
98	The Optimal Age to Stop Endoscopic Surveillance of Patients With Barrett's Esophagus Based on Sex and Comorbidity: A Comparative Cost-Effectiveness Analysis. Gastroenterology, 2021, 161, 487-494.e4.	1.3	15
99	Responsiveness of the Testing Morbidities Index in Colonoscopy. Value in Health, 2013, 16, 1046-1053.	0.3	14
100	Screening for Pancreatic Adenocarcinoma in BRCA2 Mutation Carriers: Results of a Disease Simulation Model. EBioMedicine, 2015, 2, 1980-1986.	6.1	14
101	Racial and ethnic disparities in mortality from gastric and esophageal adenocarcinoma. Cancer Medicine, 2020, 9, 5678-5686.	2.8	14
102	Microsatellite Instability is Frequently Observed in Rectal Cancer and Influenced by Neoadjuvant Chemoradiation. International Journal of Radiation Oncology Biology Physics, 2007, 68, 1584.	0.8	13
103	High-resolution microendoscopy for esophageal cancer screening in China: A cost-effectiveness analysis. World Journal of Gastroenterology, 2015, 21, 5513.	3.3	13
104	Fibroid morcellation: a shared clinical decision tool for mode of hysterectomy. European Journal of Obstetrics, Gynecology and Reproductive Biology, 2015, 195, 122-127.	1.1	13
105	Pancreatic cancer treatment costs, including patient liability, by phase of care and treatment modality, 2000–2013. Medicine (United States), 2019, 98, e18082.	1.0	13
106	Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis. Oncologist, 2019, 24, 945-954.	3.7	13
107	Unsedated Colonoscopy: Impact on Quality Indicators. Digestive Diseases and Sciences, 2020, 65, 3116-3122.	2.3	13
108	Prediction of COVID-19 Social Distancing Adherence (SoDA) on the United States county-level. Humanities and Social Sciences Communications, 2021, 8, .	2.9	13

#	Article	IF	CITATIONS
109	Assessment of the Acceptability and Feasibility of Using Mobile Robotic Systems for Patient Evaluation. JAMA Network Open, 2021, 4, e210667.	5.9	13
110	Secular Trends in Patients Diagnosed with Barrett's Esophagus. Digestive Diseases and Sciences, 2010, 55, 960-966.	2.3	12
111	Comparing Morbidities of Testing With a New Index: Screening Colonoscopy Versus Core-Needle Breast Biopsy. Journal of the American College of Radiology, 2015, 12, 295-301.	1.8	12
112	Early liver transplantation for alcoholic hepatitis: Ready for primetime?. Journal of Hepatology, 2018, 68, 380-382.	3.7	12
113	Estimates and predictors of health care costs of esophageal adenocarcinoma: a population-based cohort study. BMC Cancer, 2018, 18, 694.	2.6	12
114	Association between nonadherence to cardiovascular risk factor medications after breast cancer diagnosis and incidence of cardiac events. Cancer, 2020, 126, 1541-1549.	4.1	12
115	Heavy Alcohol Use Is Associated With Gastric Cancer: Analysis of the National Health and Nutrition Examination Survey From 1999 to 2010. American Journal of Gastroenterology, 2021, 116, 1083-1086.	0.4	12
116	Thinking green: modelling respirator reuse strategies to reduce cost and waste. BMJ Open, 2021, 11, e048687.	1.9	12
117	Deep learning on time series laboratory test results from electronic health records for early detection of pancreatic cancer. Journal of Biomedical Informatics, 2022, 131, 104095.	4.3	12
118	Preference of Endoscopic Ablation Over Medical Prevention ofÂEsophageal Adenocarcinoma by Patients With Barrett'sÂEsophagus. Clinical Gastroenterology and Hepatology, 2015, 13, 84-90.	4.4	11
119	Garlic, Silver Bullets, and Surveillance Upper Endoscopy for Barrett's Esophagus. Gastroenterology, 2013, 145, 273-276.	1.3	10
120	Cost-Effectiveness Analysis of Biomarker-Guided Treatment for Metastatic Gastric Cancer in the Second-Line Setting. Journal of Oncology, 2020, 2020, 1-10.	1.3	10
121	Threshold Analysis of the Cost-effectiveness of Endoscopic Ultrasound in Patients at High Risk for Pancreatic Ductal Adenocarcinoma. Pancreas, 2021, 50, 807-814.	1.1	10
122	Low sodium diet for gastric cancer prevention in the United States: Results of a Markov model. Cancer Medicine, 2021, 10, 684-692.	2.8	9
123	What is the clinical importance of small polyps with regard to colorectal cancer screening?. Nature Reviews Gastroenterology & Hepatology, 2006, 3, 488-489.	1.7	8
124	Tackling the hepatitis C cost problem: A test case for tomorrow's cures. Hepatology, 2015, 62, 1334-1336.	7.3	8
125	Comparative effectiveness of adjuvant chemoradiotherapy after gastrectomy among older patients with gastric adenocarcinoma: a SEER–Medicare study. Gastric Cancer, 2017, 20, 811-824.	5.3	8
126	Cost effectiveness of a novel device for improving resuscitation of apneic newborns. BMC Pediatrics, 2020, 20, 46.	1.7	8

#	Article	IF	CITATIONS
127	The Effect of Prior Colonic Imaging on Endoscopic Productivity: Potential Impact of Computed Tomographic Colonography. Clinical Gastroenterology and Hepatology, 2005, 3, 1124-1127.	4.4	7
128	Computational modeling of pancreatic cancer patients receiving FOLFIRINOX and gemcitabine-based therapies identifies optimum intervention strategies. PLoS ONE, 2019, 14, e0215409.	2.5	7
129	Cost-effectiveness Analysis of Genotype-Specific Surveillance and Preventive Strategies for Gynecologic Cancers Among Women With Lynch Syndrome. JAMA Network Open, 2021, 4, e2123616.	5.9	7
130	Cost-effectiveness of Venous Thromboembolism Prophylaxis After Hospitalization in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2022, 28, 1169-1176.	1.9	7
131	Patient and Health Care Worker Perceptions of Communication and Ability to Identify Emotion When Wearing Standard and Transparent Masks. JAMA Network Open, 2021, 4, e2135386.	5.9	7
132	Endoscopic Screening Program for Control of Esophageal Adenocarcinoma in Varied Populations: A Comparative Cost-Effectiveness Analysis. Gastroenterology, 2022, 163, 163-173.	1.3	7
133	Analysis of Aspirin-Associated Risks in Healthy Individuals. Annals of Pharmacotherapy, 2005, 39, 51-57.	1.9	6
134	Patient Preferences for the Chemoprevention of Colorectal Cancer. Digestive Diseases and Sciences, 2009, 54, 2207-2214.	2.3	6
135	Regionalization of care for women with ovarian cancer. Gynecologic Oncology, 2019, 154, 394-400.	1.4	6
136	Screening for Upper Gastrointestinal Malignancies in the United States—Which Immigrant Groups Should Be Considered High-Risk?. Gastroenterology, 2020, 158, 4-8.	1.3	6
137	Characteristics and Outcomes of Endoscopies before and during the COVID-19 Pandemic in New York. Digestive Diseases, 2021, 39, 663-672.	1.9	6
138	International cost-effectiveness analysis evaluating endoscopic screening for gastric cancer for populations with low and high risk. Gastric Cancer, 2021, 24, 878-887.	5.3	6
139	Initiation of Somatostatin analogues for neuroendocrine tumor patients: a cost-effectiveness analysis. BMC Cancer, 2021, 21, 597.	2.6	6
140	Systemic Thrombolysis, Catheterâ€Ðirected Thrombolysis, and Anticoagulation for Intermediateâ€risk Pulmonary Embolism: A Simulation Modeling Analysis. Academic Emergency Medicine, 2017, 24, 1235-1243.	1.8	5
141	The thyroid cancer policy model: A mathematical simulation model of papillary thyroid carcinoma in The U.S. population. PLoS ONE, 2017, 12, e0177068.	2.5	5
142	Lorenz Curves and Gini Coefficient Analyses Indicate Inefficiencies in Esophageal Adenocarcinoma Screening. Clinical Gastroenterology and Hepatology, 2019, 17, 560-562.e2.	4.4	5
143	Use of Bevacizumab for Elderly Patients With Stage IV Colon Cancer: Analysis of SEER-Medicare Data. Clinical Colorectal Cancer, 2019, 18, e294-e299.	2.3	5
144	Utilization of Surveillance Endoscopy for Barrett's Esophagus in Medicare Enrollees. Gastroenterology, 2020, 158, 773-775.e1.	1.3	5

#	Article	IF	CITATIONS
145	Prevalence of Extensive and Limited Gastric Intestinal Metaplasia and Progression to Dysplasia and Gastric Cancer. Digestive Diseases and Sciences, 2022, 67, 3693-3701.	2.3	5
146	Analysis of factors associated with extended recovery time after colonoscopy. PLoS ONE, 2018, 13, e0199246.	2.5	4
147	Testing for Verification Bias in Reported Malignancy Risks for Side-Branch Intraductal Papillary Mucinous Neoplasms: A Simulation Modeling Approach. American Journal of Roentgenology, 2019, 212, 596-601.	2.2	4
148	Cost-effectiveness Evaluation of Targeted Surgical and Endoscopic Therapies for Early Colorectal Adenocarcinoma Based on Biomarker Profiles. JAMA Network Open, 2020, 3, e1919963.	5.9	4
149	A modern assessment of the surgical pathologic spread and nodal dissemination of endometrial cancer. Gynecologic Oncology, 2020, 157, 329-334.	1.4	4
150	Timing of parathyroidectomy for tertiary hyperparathyroidism with end-stage renal disease: A cost-effectiveness analysis. Surgery, 2021, 169, 94-101.	1.9	4
151	Cost of inpatient admissions for immune-related adverse effects from immune checkpoint inhibitor therapy: A single center experience Journal of Clinical Oncology, 2018, 36, 3060-3060.	1.6	4
152	Severe immune-related adverse effects (irAE) requiring hospital admission in patients treated with immune checkpoint inhibitors for advanced malignancy: Temporal trends and clinical significance Journal of Clinical Oncology, 2018, 36, 3096-3096.	1.6	4
153	Costâ€effectiveness of neoadjuvant <scp>FOLFIRINOX</scp> versus gemcitabine plus nabâ€paclitaxel in borderline resectable/locally advanced pancreatic cancer patients. Cancer Reports, 2022, 5, e1565.	1.4	4
154	Endoscopic Balloon Dilation Is Cost-Effective for Crohn's Disease Strictures. Digestive Diseases and Sciences, 2022, 67, 5462-5471.	2.3	4
155	Immunogenetics of gastrointestinal cancers: A systematic review and retrospective survey of inborn errors of immunity in humans. Journal of Gastroenterology and Hepatology (Australia), 2022, 37, 973-982.	2.8	4
156	Esophageal Capsule Endoscopy for Barrett's Esophagus Screening: A Hard Pill to Swallow?. Clinical Gastroenterology and Hepatology, 2007, 5, 307-309.	4.4	3
157	318 The Cost-Effectiveness of Radiofrequency Ablation for Barrett's Esophagus. Gastroenterology, 2012, 142, S-73.	1.3	3
158	Evidence-based endoscopic management of Barrett's esophagus. Gastroenterology Report, 2015, 3, 54-62.	1.3	3
159	Effect of video monitor size on polyp detection: a prospective, randomized, controlled trial. Gastrointestinal Endoscopy, 2019, 90, 254-258.e2.	1.0	3
160	Acute Vision Loss From IgG4-Related and Bacterial Rhinosinusitis After COVID-19. JAMA Otolaryngology - Head and Neck Surgery, 2021, 147, 914.	2.2	3
161	Testing and Treating Helicobacter pylori Infection in Individuals WithÂFamily History of Gastric Cancer is Cost-effective. Gastroenterology, 2021, 161, 2051-2052.e4.	1.3	3
162	Delivery risks and outcomes associated with grand multiparity. Journal of Maternal-Fetal and Neonatal Medicine, 2022, 35, 7708-7716.	1.5	3

#	Article	IF	CITATIONS
163	Delay in receipt of newly prescribed oral anticancer drugs Journal of Clinical Oncology, 2019, 37, 6541-6541.	1.6	3
164	Risk of corticosteroid treatment and hospitalization after checkpoint inhibitor and radiation therapy in patients with cancer. Cancer, 2022, 128, 819-827.	4.1	3
165	Modeling the Cost-Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer in South African Public Hospitals. JCO Global Oncology, 2021, 7, 1730-1741.	1.8	3
166	Digital subtraction bowel cleansing (DSBC) in CT colonography (CTC): Experience in 70 patients. Gastroenterology, 2003, 124, A114.	1.3	2
167	Cost-Effectiveness of Prophylactic Surgery for Duodenal Cancer in Familial Adenomatous Polyposis. Cancer Epidemiology Biomarkers and Prevention, 2009, 18, 2677-2684.	2.5	2
168	Computed Tomography Findings as a Novel Predictor of Alcohol-Associated Hepatitis Outcomes. Digestive Diseases and Sciences, 2020, 65, 312-321.	2.3	2
169	Toxicity after adjuvant therapy for stage III uterine cancer. Gynecologic Oncology, 2020, 159, 737-743.	1.4	2
170	Delays in colonoscopy start time are associated with reductions in adenoma detection rates. Digestive and Liver Disease, 2020, 52, 905-908.	0.9	2
171	Utility and Cost-Effectiveness of a Nonendoscopic Approach to Barrett's Esophagus Surveillance After Endoscopic Therapy. Clinical Gastroenterology and Hepatology, 2022, 20, e51-e63.	4.4	2
172	Minimal Associations between Short-Term Dietary Intake and Salivary Microbiome Composition. Microorganisms, 2021, 9, 1739.	3.6	2
173	Infliximab vs. Adalimumab for Crohn's disease: authors' reply. Alimentary Pharmacology and Therapeutics, 2008, 28, 1266-1267.	3.7	1
174	Mo1668 Mucosal Healing is a Cost-Effective Endpoint With Biologic Therapy in Crohns Disease - Results From a Decision Analysis. Gastroenterology, 2012, 142, S-654.	1.3	1
175	Tu1112 Aspirin Protective Against Barrett's Esophagus: Results of Multivariate Regression Analysis. Gastroenterology, 2012, 142, S-749.	1.3	1
176	Mo1134 Accuracy of a High Resolution, Low-Cost Microendoscope for the Early Detection of Esophageal Squamous Cell Neoplasia: a Prospective, International, Multicenter Trial. Gastroenterology, 2014, 146, S-566.	1.3	1
177	Sa1275 Patient Decision-Making and Clinical Outcomes Following Endoscopic Therapy or Esophagectomy for Barrett's Neoplasia. Gastroenterology, 2016, 150, S266.	1.3	1
178	Proton Pump Inhibitors and Dementia Incidence. JAMA Neurology, 2016, 73, 1027.	9.0	1
179	Patient decision-making and clinical outcomes following endoscopic therapy or esophagectomy for Barrett's neoplasia. Endoscopy International Open, 2017, 05, E1128-E1135.	1.8	1

7.3 1

#	Article	IF	CITATIONS
181	A quantitative exploration of gastrointestinal bleeding in intensive care unit patients. PLoS ONE, 2019, 14, e0212040.	2.5	1
182	Surveillance Cessation for Barrett's Esophagus: A Survey of Gastroenterologists. American Journal of Gastroenterology, 2021, 116, 1730-1733.	0.4	1
183	Tissue scale agent-based simulation of premalignant progressions in Barrett's esophagus. Simulation, 0, , 003754972110400.	1.8	1
184	Cost-effectiveness of immune checkpoint inhibition in metastatic gastric and esophageal tumors Journal of Clinical Oncology, 2018, 36, 56-56.	1.6	1
185	Use of nonclinical staff to coordinate oral anticancer drug prescriptions Journal of Clinical Oncology, 2019, 37, 72-72.	1.6	1
186	Cost-effectiveness of universal screening for germline BRCA mutations in metastatic pancreatic cancer Journal of Clinical Oncology, 2022, 40, 536-536.	1.6	1
187	Genetic testing to guide screening for pancreatic ductal adenocarcinoma: Results of a microsimulation model. Pancreatology, 2022, 22, 760-769.	1.1	1
188	Hp eradication rates and symptoms in patients with proven peptic ulcers. American Journal of Gastroenterology, 2000, 95, 2454-2454.	0.4	0
189	Helicobacter pylori eradication rates and symptoms in patients with endoscopically diagnosed peptic ulcers. Gastroenterology, 2000, 118, A1248.	1.3	0
190	Screening first degree relatives of patients with Celiac Disease. Gastroenterology, 2003, 124, A419.	1.3	0
191	Cost-effectiveness of aspirin chemoprevention for Barrett's esophagus. Gastroenterology, 2003, 124, A240.	1.3	0
192	S1170 The Effect of Virtual Colonoscopy On Colorectal Cancer Screening in a Nonadherent Population. Gastroenterology, 2008, 134, A-193.	1.3	0
193	Surgical Versus Endoscopic Therapy for Barrett's Esophagus with Intramucosal Neoplasia: Determinants of Treatment Modality in a Tertiary Referral Center. Gastrointestinal Endoscopy, 2008, 67, AB177.	1.0	0
194	How useful is histologic confirmation of intestinal metaplasia in patients with long-segment Barrett's esophagus?. Nature Reviews Gastroenterology & Hepatology, 2008, 5, 140-141.	1.7	0
195	S1290 The Management of Branch Duct Intraductal Papillary Mucinous Neoplasm: A Cost-Effectiveness Analysis. Gastroenterology, 2009, 136, A-230.	1.3	0
196	T1925 The Prevalence of Barrett's Esophagus in the US: Estimate Confirmation Using a Simulation Model and SEER Data. Gastroenterology, 2009, 136, A-602.	1.3	0
197	T1884 Temporal Trends in Patients Newly Diagnosed with Barrett's Esophagus in a Single-Center Cohort, 1997-2007. Gastroenterology, 2009, 136, A-593.	1.3	0
198	Tu1171 Green Tea and Esophageal Cancer Risk: A Meta-Analysis of Epidemiologic Studies. Gastroenterology, 2012, 142, S-765.	1.3	0

#	Article	IF	CITATIONS
199	786 Effectiveness and Cost-Effectiveness of Once-Only Screening for Colorectal Cancer With Colonoscopy or Computed Tomographic Colonography. Gastroenterology, 2012, 142, S-141-S-142.	1.3	0
200	Su1457 Predictors of Adenocarcinoma Development After Endoscopic Ablation Therapy for Barrett's Esophagus. Gastrointestinal Endoscopy, 2013, 77, AB330-AB331.	1.0	0
201	Sa1822 Patient Preferences for Prevention of Esophageal Adenocarcinoma in Barrett's Esophagus, Endoscopic Ablation Versus Chemoprevention: A Prospective Multicenter Study. Gastroenterology, 2014, 146, S-304.	1.3	0
202	Sa1864 Aspirin Downregulates Cell Survival and mTOR Effector pS6K in Barrett's Esophagus Patients: Data From a Randomized, Double-Blind, Phase II Chemoprevention Trial. Gastroenterology, 2014, 146, S-315.	1.3	0
203	Sa1859 Randomized Double Blind Placebo Controlled Phase II Trial of Barrett's Esophagus Chemoprevention With Metformin. Gastroenterology, 2014, 146, S-314.	1.3	0
204	Sa1025 Surgical Versus Endoscopic Management of Flat and Depressed Polyps Found in the Right Colon: Results of a Decision Analysis. Gastroenterology, 2015, 148, S-200.	1.3	0
205	Endoscopic therapy versus surgery for T1 colon cancer: defining model clinical practice. Gastrointestinal Endoscopy, 2016, 84, 995-996.	1.0	0
206	235 Accuracy of Post-Hoc High-Resolution Microendoscopy for Diagnosis of Esophageal Squamous Cell Neoplasia. Gastroenterology, 2016, 150, S55.	1.3	0
207	Acceptance of Surgical Treatment for Adolescent Obesity—Reply. JAMA Surgery, 2017, 152, 802.	4.3	0
208	Screening for Esophageal Squamous Cell Carcinoma. , 2019, , 291-301.e2.		0
209	Cost-effectiveness analysis of platinum-based chemotherapy treatment options for germline BRCA-mutated locally advanced/borderline resectable pancreatic cancer Journal of Clinical Oncology, 2021, 39, e16246-e16246.	1.6	0
210	Cost-effectiveness of adjuvant chemotherapy for stage III colon cancer in the South African public healthcare setting Journal of Clinical Oncology, 2021, 39, e18849-e18849.	1.6	0
211	Gastric Cancer:. Gastrointestinal Endoscopy Clinics of North America, 2021, 31, xv-xviii.	1.4	0
212	Responses to Wu et al. and Wang et al American Journal of Gastroenterology, 2021, Publish Ahead of Print, .	0.4	0
213	Cost-Effectiveness of Endoscopic Therapy for Barrett's Esophagus. , 2009, , 165-185.		0
214	Neoadjuvant FOLFIRINOX for patients with borderline resectable or locally advanced pancreatic cancer: Results of a decision analysis Journal of Clinical Oncology, 2017, 35, 4117-4117.	1.6	0
215	Disparities in cancer outcomes across age, sex, and race/ethnicity among pancreatic cancer patients Journal of Clinical Oncology, 2017, 35, e18071-e18071.	1.6	0
216	Nivolumab versus nivolumab with ipilimumab versus trifluridine/tipiracil for metastatic microsatellite instability-high colorectal cancer: A modeling decision analysis Journal of Clinical Oncology, 2018, 36, 829-829.	1.6	0

#	Article	IF	CITATIONS
217	Cost-effectiveness of single versus dual immune checkpoint blockade for chemotherapy-refractory esophageal, GE junction, and gastric cancers Journal of Clinical Oncology, 2018, 36, e16089-e16089.	1.6	0
218	Cost-effectiveness of nivolumab vs. ipilimumab/nivolumab vs. trifluridine/tipiracil or mFOLFOX6/cetuximab for microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer Journal of Clinical Oncology, 2018, 36, e15134-e15134.	1.6	0
219	Second-line treatment of metastatic gastric cancer in the era of predictive biomarkers: A cost-effectiveness analysis Journal of Clinical Oncology, 2019, 37, e15517-e15517.	1.6	0
220	Treatment of early stage (T1) esophageal adenocarcinoma: Personalizing the best therapy choice. World Journal of Meta-analysis, 2019, 7, 406-417.	0.1	0
221	Databases for Gastrointestinal Clinical and Public Health Research: Have Database, Will Research. Gastroenterology, 2022, 163, 31-34.	1.3	0
222	Deep learning on time series laboratory test results from electronic health records for early detection of pancreatic cancer Journal of Clinical Oncology, 2022, 40, e16268-e16268.	1.6	0
223	Cost-effectiveness of adjuvant chemotherapy for patients with high-risk stage II and stage III colon cancer in South Africa Journal of Clinical Oncology 2022, 40, 6599-6599	1.6	0